Resultado de búsqueda
23 de mar. de 2021 · Background: In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists ...
The authors assessed the safety and efficacy of antithrombotic regimens according to HAS-BLED and CHA 2 DS 2-VASc scores in AUGUSTUS (The Open-Label, 2 × 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention).
Aquí nos gustaría mostrarte una descripción, pero el sitio web que estás mirando no lo permite.
2 de jul. de 2019 · AUGUSTUS is the first trial with a two-by-two factorial design in patients with atrial fibrillation (AF) on combined antithrombotic therapy after an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), respectively. 1 Thereby, it allows the independent evaluation of the effects of prescribing apixaban instead of warfarin and skipping aspirin in the same patient ...
3 de dic. de 2019 · Stephan Windecker 1 , Renato D Lopes 2 , Tyler Massaro 2 , Charlotte Jones-Burton 3 , Christopher B Granger 2 , Ronald Aronson 3 , Gretchen Heizer 2 , Shaun G Goodman 4 5 , Harald Darius 6 , W Schuyler Jones 2 , Michael Aschermann 7 , David Brieger 8 , Fernando Cura 9 , Thomas Engstrøm 10 , Viliam Fridrich 11 , Sigrun Halvorsen 12 , Kurt Huber ...
29 de ago. de 2023 · The AUGUSTUS trial was a two factorial, randomized controlled trial that randomized patients with atrial fibrillation who had an acute coronary syndrome or percutaneous coronary intervention to either aspirin or placebo and to either a vitamin K antagonist (VKA) or apixaban, a factor Xa inhibitor.
26 de sept. de 2019 · The details of the AUGUSTUS trial (ClinicalTrials.gov. Unique identifier: NCT02415400) design and results have been reported. 11 , 12 In brief, AUGUSTUS was an international, randomized, clinical trial with a 2×2 factorial design in which patients with AF and ACS and/or undergoing PCI and taking a P2Y 12 inhibitor were factorially randomized to apixaban or VKA and aspirin or placebo.
